BusinessPeregrine Pharmaceuticals Provides Update on Planned Expansion of Bavituximab Clinical Program in Lung, Breast and Other CancersBy Nasdaq OMXJan 11, 2016, 1:05 PM UTC
BusinessPeregrine Pharmaceuticals and National Comprehensive Cancer Network (NCCN) Form Clinical Collaboration to Evaluate Novel Cancer Treatment Combinations With BavituximabBy Nasdaq OMXJan 6, 2016, 1:05 PM UTC
